Quantification of the effect of treatment duration on local-regional failure after definitive concurrent chemotherapy and intensity-modulated radiation therapy for squamous cell carcinoma of the head and neck

Head and Neck

Volumn 35, Issue 5, 2013, Pages 684-688

  Platek, Mary E ^a,e   McCloskey, Susan A ^b   Cruz, Myra ^a   Burke, Mark S ^c   Reid, Mary E ^a   Wilding, Gregory E ^a   Rigual, Nestor R ^a   Popat, Saurin R ^c,d   Loree, Thom R ^c   Gupta, Vishal ^a   Warren, Graham W ^a   Sullivan, Maureen ^a   Hicks Jr , Wesley L ^a   Singh, Anurag K ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c ERIE COUNTY MEDICAL CENTER   (United States)

^d UNIVERSITY AT BUFFALO   (United States)

^e NEW YORK UNIVERSITY   (United States)

Author keywords

anemia; concurrent chemoradiation therapy; squamous cell carcinoma of the head and neck; treatment delay; treatment failure

Indexed keywords

CISPLATIN;

ADULT; AGED; ARTICLE; CHEMORADIOTHERAPY; CONTROLLED STUDY; FEMALE; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RADIATION DOSE; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME; TUMOR GROWTH; CARCINOMA, SQUAMOUS CELL; DISEASE COURSE; HEAD AND NECK NEOPLASMS; MIDDLE AGED; MULTIVARIATE ANALYSIS; TIME; TUMOR RECURRENCE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; CHEMORADIOTHERAPY; DISEASE PROGRESSION; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; RADIOTHERAPY, INTENSITY-MODULATED; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT FAILURE;

EID: 84876025731     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.23024     Document Type: Article

References (29)

1. Adelstein DJ, Saxton JP, Rybicki LA, et al. Multiagent concurrent chemoradiotherapy for locoregionally advanced squamous cell head and neck cancer: mature results from a single institution. J Clin Oncol 2006; 24: 1064-1071.
2. Brizel DM, Albers ME, Fisher SR, et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med 1998; 338: 1798-1804.
3. de Arruda FF, Puri DR, Zhung J, et al. Intensity-modulated radiation therapy for the treatment of oropharyngeal carcinoma: the Memorial Sloan-Kettering Cancer Center experience. Int J Radiat Oncol Biol Phys 2006; 64: 363-373.
4. Kies MS, Haraf DJ, Rosen F, et al. Concomitant infusional paclitaxel and fluorouracil, oral hydroxyurea, and hyperfractionated radiation for locally advanced squamous head and neck cancer. J Clin Oncol 2001; 19: 1961-1969.
5. American Cancer Society. Cancer Facts and Figures 2009. Atlanta, GA. American Cancer Society; 2010.
6. Suwinski R, Sowa A, Rutkowski T, Wydmanski J, Tarnawski R, Maciejewski B,. Time factor in postoperative radiotherapy: a multivariate locoregional control analysis in 868 patients. Int J Radiat Oncol Biol Phys 2003; 56: 399-412.
7. Robertson C, Robertson AG, Hendry JH, et al. Similar decreases in local tumor control are calculated for treatment protraction and for interruptions in the radiotherapy of carcinoma of the larynx in four centers. Int J Radiat Oncol Biol Phys 1998; 40: 319-329.
8. Hliniak A, Maciejewski B, Trott KR,. The influence of the number of fractions, overall treatment time and field size on the local control of cancer of the skin. Br J Radiol 1983; 56: 596-598.
9. Maciejewski B, Withers HR, Taylor JM, Hliniak A,. Dose fractionation and regeneration in radiotherapy for cancer of the oral cavity and oropharynx: tumor dose-response and repopulation. Int J Radiat Oncol Biol Phys 1989; 16: 831-843.
10. Kwong DL, Sham JS, Chua DT, Choy DT, Au GK, Wu PM,. The effect of interruptions and prolonged treatment time in radiotherapy for nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 1997; 39: 703-710.
11. Rades D, Stoehr M, Kazic N, et al. Locally advanced stage IV squamous cell carcinoma of the head and neck: impact of pre-radiotherapy hemoglobin level and interruptions during radiotherapy. Int J Radiat Oncol Biol Phys 2008; 70: 1108-1114.
12. Platek ME, Reid ME, Wilding GE, et al. Pretreatment nutritional status and locoregional failure of patients with head and neck cancer undergoing definitive concurrent chemoradiation therapy. Head Neck 2011; 33: 1561-1568.
13. McCloskey SA, Jaggernauth W, Rigual NR, et al. Radiation treatment interruptions greater than one week and low hemoglobin levels (12 g/dL) are predictors of local regional failure after definitive concurrent chemotherapy and intensity-modulated radiation therapy for squamous cell carcinoma of the head and neck. Am J Clin Oncol 2009; 32: 587-591.
14. Hamwi GJ,. Therapy: changing dietary needs. In:, Danowski TS, editor. Diabetes mellitus: diagnosis and treatment. New York, NY: American Diabetes Association; 1964. pp. 73-78.
15. Nangia S, Chufal KS, Tyagi A, Bhatnagar A, Mishra M, Ghosh D,. Selective nodal irradiation for head and neck cancer using intensity-modulated radiotherapy: application of RTOG consensus guidelines in routine clinical practice. Int J Radiat Oncol Biol Phys 2010; 76: 146-153.
16. von Meyenfeldt M,. Cancer-associated malnutrition: an introduction. Eur J Oncol Nurs 2005; 9 Suppl 2: S35-S38.
17. Harrison LB, Chadha M, Hill RJ, Hu K, Shasha D,. Impact of tumor hypoxia and anemia on radiation therapy outcomes. Oncologist 2002; 7: 492-508.
18. Mohan R, Wu Q, Manning M, Schmidt-Ullrich R,. Radiobiological considerations in the design of fractionation strategies for intensity-modulated radiation therapy of head and neck cancers. Int J Radiat Oncol Biol Phys 2000; 46: 619-630.
19. Dubben HH,. Local control, TCD50 and dose-time prescription habits in radiotherapy of head and neck tumours. Radiother Oncol 1994; 32: 197-200.
20. Withers HR, Taylor JM, Maciejewski B,. The hazard of accelerated tumor clonogen repopulation during radiotherapy. Acta Oncol 1988; 27: 131-146.
21. Withers HR, Maciejewski B, Taylor JM, Hliniak A,. Accelerated repopulation in head and neck cancer. Front Radiat Ther Oncol 1988; 22: 105-110.
22. Peters LJ, Withers HR,. Applying radiobiological principles to combined modality treatment of head and neck cancer-the time factor. Int J Radiat Oncol Biol Phys 1997; 39: 831-836.
23. Wyatt RM, Beddoe AH, Dale RG,. The effects of delays in radiotherapy treatment on tumour control. Phys Med Biol 2003; 48: 139-155.
24. Marcu L, van Doorn T, Olver I,. Modelling of post-irradiation accelerated repopulation in squamous cell carcinomas. Phys Med Biol 2004; 49: 3767-3779.
25. Slevin NJ, Hendry JH, Roberts SA, Agren-Cronqvist A,. The effect of increasing the treatment time beyond three weeks on the control of T2 and T3 laryngeal cancer using radiotherapy. Radiother Oncol 1992; 24: 215-220.
26. Awwad HK, Khafagy Y, Barsoum M, et al. Accelerated versus conventional fractionation in the postoperative irradiation of locally advanced head and neck cancer: influence of tumour proliferation. Radiother Oncol 1992; 25: 261-266.
27. Corry J, Rischin D,. Strategies to overcome accelerated repopulation and hypoxia-what have we learned from clinical trials? Semin Oncol 2004; 31: 802-808.
28. Rosenthal DI,. Consequences of mucositis-induced treatment breaks and dose reductions on head and neck cancer treatment outcomes. J Support Oncol 2007; 5 (9 Suppl 4): 23-31.
29. Chaturvedi AK, Kleinerman RA, Hildesheim A, et al. Second cancers after squamous cell carcinoma and adenocarcinoma of the cervix. J Clin Oncol 2009; 27: 967-973.